Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Articles tagged with "Senate"

U.S. Senators Tell Drug Company Execs Pricing Is Morally Repugnant

Yasmeen Abutaleb & Michael Erman  |  February 28, 2019

WASHINGTON/NEW YORK (Reuters)—U.S. Senators called drug pricing practices “morally repugnant” and told drug company executives they do not want to hear them blame others for the high prices, taking an aggressive stance at the start of a Senate hearing on the rising costs of prescription medicines. Executives from Abbvie Inc., AstraZeneca PLC., Sanofi SA, Pfizer…

U.S. Senators Reach Bipartisan Deal on Obamacare Backed by Trump

Yasmeen Abutaleb & Richard Cowan  |  October 18, 2017

WASHINGTON (Reuters)—On Tuesday, two U.S. senators announced a bipartisan breakthrough to shore up Obamacare for two years by reviving federal subsidies for health insurers that President Donald Trump planned to scrap, and the president voiced support for the plan. The agreement worked out by Sen. Lamar Alexander (R-Tenn.) and Sen. Patty Murray (D-Wash.) would meet…

McCain to Return for Pivotal U.S. Senate vote on Healthcare

James Oliphant  |  July 25, 2017

WASHINGTON (Reuters)—Sen. John McCain (R-Az.) will return to the U.S. capitol on Tuesday to play what could be a crucial role in salvaging Republican efforts to repeal Obamacare and keep their years-long pledge to unwind the 2010 healthcare overhaul. McCain, who is battling brain cancer, is set to help decide whether the repeal push will…

Congress Must Shore Up Insurance Markets If Obamacare Repeal Fails

Reuters Staff  |  July 7, 2017

WASHINGTON (Reuters)—U.S. Senate Majority Leader Mitch McConnell (R-Ky.) said on Thursday that Congress must act to shore up private health insurance markets if it fails to repeal Obamacare, comments seen as providing a pathway to a bipartisan deal to fix the health system. Speaking at a luncheon in his home state of Kentucky, McConnell said,…

U.S. Democrats Criticize Senate’s All-Male Healthcare Group

John Whitesides & Sarah N. Lynch  |  May 9, 2017

WASHINGTON (Reuters)—U.S. Democrats on Sunday criticized the lack of women on a working group in the Republican-led Senate that will craft a plan to pass legislation to repeal and replace Obamacare. As the Senate begins to wrestle with a Republican healthcare bill narrowly approved by the House of Representatives last week, senators questioned why the…

RheumPAC Advances Policy Issues of Rheumatology Professionals

The RheumPAC Committee  |  December 13, 2016

Our elected officials make decisions every day that affect our lives and the lives of our patients. These decisions are often based on input they have received from advocates and lobbyists, constituents and fellow lawmakers. Regardless of our ideals, money plays a role in this decision making, because political contributions facilitate access to legislators and…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences